EO provides a digital health platform that creates personalized, clinician‑approved care plans for cannabinoid therapy. Users submit health information and receive evidence‑based product, dose, and usage guidance for FDA‑compliant, organic hemp products, with ongoing plan adjustments, expert support, and up to 20% product discounts.
Funding
$7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with cancer, chronic pain, sleep issues, and other health conditions often turn to cannabinoids for symptom relief but lack reliable, clinician‑guided dosing and product recommendations, leading to suboptimal outcomes and safety concerns.
Solution
EO offers a digital health platform that creates personalized, clinician‑approved care plans for cannabinoid therapy. Users provide health information and receive product, dose, and usage guidance that is continuously refined through ongoing feedback. All products are federally legal, precision‑dosed, non‑combustible forms made from 100% organic hemp, produced in GMP‑certified facilities, and shipped directly to the patient. The platform’s proprietary Bayesian data models integrate patient‑reported outcomes, peer‑reviewed research, and real‑world data from thousands of users to generate evidence‑based recommendations. Clinicians review and approve each plan, ensuring medical oversight while reducing administrative burden. Patients also receive up to 20% discount on all products and can message the expert team at any time.
Target Audience
Primary users are cancer patients, older adults, and individuals with chronic pain, sleep disturbances, nausea, or anxiety who seek medically supervised cannabinoid therapy, as well as their healthcare providers seeking structured symptom‑management solutions.
Features
- Clinician‑designed, precision‑dosed cannabinoid products (inhalers, gummies, tablets, tinctures, topicals, beverage shots) that are non‑combustible and <0.3% THC, compliant with the Farm Bill
- Automated care plan generation using validated Bayesian models that incorporate patient inputs, medical history, medication list, and daily schedule
- Continuous plan adjustment through regular patient feedback loops and clinician review, enabling adaptive dosing and monitoring of efficacy and side effects
- Secure, cloud‑based data platform that aggregates outcomes from over 20,000 users to inform recommendations and support real‑world evidence generation
- Integrated expert support: patients can message a clinician‑led team anytime for dosing, interaction, or safety questions at no cost
- Discounts of up to 20% on all products for plan participants, making high‑quality cannabinoid therapy affordable
- Compliance and safety ensured by 3rd‑party testing, GMP‑certified manufacturing, and full FDA‑compliant labeling